

### **In the Claims**

Applicants submit herewith a marked-up version of the claims. Entry of the amendments is requested. Please amend claims 1, 10, 11, 18, and 33 as shown on the marked-up versions of the claims contained herein.

The submitted marked-up versions of the claims follows standard amendment rules, wherein added text has been underlined and deleted text has been bracketed. The status of each claim is additionally provided.

### **Remarks to Amended Claims**

Claims 1, 11, and 33 have been amended to define the analyte detector for cardiac troponin to include a troponin antibody containing at least one of the two fluorescent dyes. Support for claim the troponin antibody having at least one of the two fluorescent dyes is specifically shown in Figures 4A and 4B and is discussed in the specification specifically in paragraphs [0053] and [0054] wherein the second florescent tag is contained on a second antibody. An alternative embodiment is shown in Figure 5, and in the specification in paragraph [0063] wherein the second fluorescent tag is contained in the substrate.

Claims 11 and 17 have additionally been amended as recommended by the Examiner to indicate the device has been adapted to be implanted. Support for a partial or totally implanted device is shown in Figures 1, 2, and 3 and as discussed starting at paragraphs [0027], [0032], and [0043], respectively.

Claim 38 as been amended to indicate that the method of Claim 1 has occurred, as conditions precedent, after an ischemic stroke, viral infection, or after having received administration of insulin, an illegal drug, a biological toxin, or a biological warfare agent. Changes made were to recite an active method step precedent to the steps of Claim 1 and to make the claim more readable.